Tetanus Toxin Peptide Conjugate for Antigen Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines, especially those against cancer, face challenges in inducing effective immune responses due to poor uptake by antigen-presenting cells, and existing methods to enhance immunogenicity are either inefficient or costly, such as using α-gal epitopes, which are difficult to synthesize.
Innovation Solution
A conjugate is developed comprising a peptide with the amino acid sequence GITELKKL (residues 383-390 of the tetanus toxin heavy chain) or sequences with high sequence identity, which is bound by antibodies in at least 50% of serum samples from individuals vaccinated with tetanus toxoid, conjugated to an antigen or vehicle, to enhance antigen targeting and processing by antigen-presenting cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines are used, then they contain all components required for immune response induction, but they have poor uptake by antigen-presenting cells resulting in limited immunogenicity
Solution Approach 1:
The patent uses pre-existing anti-tetanus toxin antibodies as intermediaries to mediate the delivery of vaccine antigens to antigen-presenting cells. The conjugate comprises a tetanus toxin peptide coupled to the vaccine antigen, and pre-existing antibodies against the peptide form immune complexes that are recognized by Fcγ receptors on antigen-presenting cells, enabling efficient uptake and processing of the antigen.
2Reliability
If immune complexes with IgG antibodies are formed to improve immunogenicity, then uptake by antigen-presenting cells is enhanced, but the Fc domain of many monoclonal antibodies has poor interaction with Fc-gamma receptor resulting in ineffective targeting
Solution Approach 1:
The patent exploits the self-service capability of pre-existing natural antibodies in the patient's serum. These endogenous anti-tetanus toxin antibodies automatically form immune complexes with the conjugate and mediate their own delivery to antigen-presenting cells via Fcγ receptor binding, eliminating the need to engineer specialized antibodies with optimized Fc domains.
3Reliability
If α-gal epitopes are used to enhance targeting to antigen-presenting cells, then immunogenicity is improved, but synthesizing α-gal epitopes is more difficult and expensive compared to regular peptides
Solution Approach 1:
The patent replaces the expensive and difficult-to-synthesize α-gal epitopes with a simple, short peptide sequence (GITELKKL) derived from tetanus toxin. This peptide is easily synthesized using standard peptide chemistry methods and serves as an effective targeting moiety that leverages pre-existing natural antibodies, providing a cost-effective and manufacturable solution.
4Reliability
If peptide conjugates are used to improve antigen targeting, then uptake by antigen-presenting cells is enhanced, but production reproducibility becomes challenging
Solution Approach 1:
The patent segments the vaccine conjugate into two independent components: a standardized tetanus toxin peptide moiety (GITELKKL) and the vaccine-specific antigen. The peptide portion is uniformly synthesized and purified to high standards, while the antigen can be varied without affecting the targeting mechanism. This modular design ensures consistent immunogenicity across different vaccine formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate significantly improves vaccine immunogenicity by efficiently targeting antigens to antigen-presenting cells, inducing robust humoral and cellular immune responses, and can be used in both prophylactic and therapeutic applications, including cancer treatment.
Implementation Method 1
the peptide, when subjected to serum samples from at least 10 human subjects that had been vaccinated with tetanus toxoid is in at least 50% of the serum samples bound by antibodies from the serum samples
Data Source
AI summary
The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL (residues 383-390 of SEQ ID NO: 3) for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.